Participating Clinical Centers
Once-Daily Oral Iron Chelator Exjade® Receives Approval in the U.S.
Thursday, November 3rd, 2005
Novartis announced today the first approval worldwide for Exjade® (deferasirox) -- the first and only once-daily oral iron chelator -- by the U.S. Food and Drug Administration. Exjade® has been approved for the treatment of chronic iron overload due to blood transfusions in adults and children age two and older.
Exjade® is the only iron chelator administered as a drink (the tablets are dispersed in a glass of orange juice, apple juice or water), compared to the current standard of care, which often requires a subcutaneous infusion lasting eight to 12 hours per night, for five to seven nights a week for as long as the patient continues to receive blood transfusions or has excess iron within the body. As a result, many patients may have stopped or avoided iron chelation therapy, thus risking the toxic effects of iron overload.
To learn more about Exjade®, patients and physicians in the U.S. can call 1-888-NOW-NOVA (1-888-669-6682). To learn more about ongoing Exjade® clinical trials, health care providers can call either 1-800-340-6843 in the U.S., or +44 (0) 1506 814899 outside the U.S.
For More Information:
AAMDS Exjade (Deferasirox) Information Page
| Back to the main news index |
